Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-19T05:10:08.329Z Has data issue: false hasContentIssue false

P.120 Case series: Clinical and genetic spectrum of SCN8A-related disorders in British Columbia

Published online by Cambridge University Press:  05 January 2022

M Hebbar
Affiliation:
(Vancouver)*
N Al-Taweel
Affiliation:
(Vancouver)
I Gill
Affiliation:
(Vancouver)
C Boelman
Affiliation:
(Vancouver)
RA Dean
Affiliation:
(Burnaby)
SJ Goodchild
Affiliation:
(Burnaby)
J Mezeyova
Affiliation:
(Burnaby)
NG Shuart
Affiliation:
(Burnaby)
JP Johnson Jr.
Affiliation:
(Burnaby)
J Lee
Affiliation:
(Vancouver)
A Michoulas
Affiliation:
(Vancouver)
LL Huh
Affiliation:
(Vancouver)
L Armstrong
Affiliation:
(Vancouver)
MB Connolly
Affiliation:
(Vancouver)
M Demos
Affiliation:
(Vancouver)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Children with pathogenic variations in SCN8A can present with early infantile epileptic encephalopathy-13, benign familial infantile seizures-5 or intellectual disability alone without epilepsy. In this case series, we discuss six children with variants in SCN8A managed at BC Children’s Hospital. Methods: We describe clinical and genetic results on six individuals with SCN8A variants identified via clinical or research next-generation sequencing. Functional consequences of two SCN8A variants were assessed using electrophysiological analyses in transfected cells. Results: Clinical findings ranged from normal development with well-controlled epilepsy to significant developmental delay with treatment-resistant epilepsy. Phenotypes and genotypes in our cohort are described in the table below. Functional analysis supported gain-of-function in P2 and loss-of-function in P4. Conclusions: Our cohort expands the clinical and genotypic spectrum of SCN8A-related disorders. We establish functional evidence for two missense variants in SCN8A, including LoF variant in a patient with intellectual disability, and autism spectrum disorder without seizures.

Table for P.120

PatientsAge/SexDevelopmentAge of seizure onsetEpilepsy typeCurrent antiseizure medicationSeizure frequencyGene variant/FunctionInheritance
P114y/FProfound GDD5mInfantile spasms, LGS, hyperkinetic movementsClobazamDailyc.1238C>A (p.Ala413Asp)De novo
P26y/FNormal3-7mFocal epilepsyCarbamazepineSeizure freec.5630A>G (p.Asn1877Ser)/GoFPaternal
P34y/FNormal12mFocal epilepsyClobazam, topiramateSeizure freec.4447G>A (p.Glu1483Lys)De novo
P46y/FGDD, autism3y - EEG abnormality only-Sodium valproate (discontinued)No clinical seizurec.971G>A (p.Cys324Tyr)/LoF, VUS in KCNQ3De novo
P57y/MGDD5mGeneralized seizuresEthosuximide, acetazolamideDailyc.773C>T (p.Thr258Ile)De novo
P619y/FNormal10yFocal epilepsyCarbamazepineSeizure freec.986A>G (p.Asp329Gly)De novo

Abbreviations: *Father with similar history, y Years, m Months, GDD Global developmental delay, LGS Lennox-Gastaut syndrome, VUS Variant of unknown significance, LoF Loss-of-function, GoF Gain-of-function, EEG Electroencephalogram, F - Female, M - Male, CBD - Cannabidiol

Type
Poster Presentations
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation